| Literature DB >> 30782703 |
Ling Zhao1, Ping Pang2, Li Zang1, Yukun Luo3, Fulin Wang4, Guoqing Yang1, Jin Du1, Xianling Wang1, Zhaohui Lyu1, Jingtao Dou1, Yiming Mu1.
Abstract
OBJECTIVES: This study aims to summarise the features and trends of thyroid carcinoma in the past two decades in China. DESIGN, SETTING AND PARTICIPANTS: Clinical data obtained from 10 798 patients treated by thyroidectomy from 1994 to 2015 at the Department of General Surgery of the People's Liberation Army General Hospital, Beijing, China were retrospectively analysed. OUTCOME MEASURES: Incidence and histopathological features of thyroid cancer were compared and the risk factors for local lymph node metastasis analysed.Entities:
Keywords: microptc; papillary thyroid carcinoma; thyroid cancer
Mesh:
Year: 2019 PMID: 30782703 PMCID: PMC6347868 DOI: 10.1136/bmjopen-2018-023334
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015
| Period | 94–95* | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | Total | P value |
| Benign, | 114 (83.2) | 136 (86.1)†‡ | 169 (88.0)†‡ | 268 (83.0)† | 286 (80.1)†‡ | 495 (79.2)‡ | 535 (71.4)†‡ | 738 (64.6)†‡ | 901 (52.4)†‡ | 1033 (42.2)†‡ | 890 (30.2)†‡ | 5563 (51.5) | <0.001 |
| Cancer, | 23 (16.8) | 22 (13.9)*† | 23 (12.0)*† | 55 (17.0)* | 71 (19.9)*† | 130 (20.8)† | 214 (28.6)*† | 405 (35.4)*† | 817 (47.6)*† | 1413 (57.8)*† | 2060 (69.8)*† | 5235 (48.5) | |
| Total | 137 | 158 | 192 | 323 | 357 | 625 | 749 | 1143 | 1718 | 2446 | 2950 | 10 798 |
*The last 2 digits of the years are displayed (hereafter).
†Percentages significantly different from the previous year.
‡Percentages significantly different within the period of 94–95.
Pathological classification of all thyroid malignancies from 1994 to 2015
| Period | 94–95 | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | P for difference | P for trend |
| PTC, | 15 (65.3) | 17 (77.3) | 17 (73.9) | 39 (70.9) | 50 (70.4) | 107 (82.3) | 185 (86.4) | 383 (94.6) | 768 (94.0) | 1376 (97.4) | 2023 (98.2) | <0.001 | <0.001 |
| FTC, | 3 (13.0) | 1 (4.5) | 4 (17.3) | 10 (18.1) | 9 (12.7) | 17 (13.1) | 18 (8.4) | 9 (2.2) | 25 (3.0) | 17 (1.2) | 20 (0.9) | <0.001 | <0.001 |
| MTC, | 1 (4.3) | 2 (9.1) | 1 (4.3) | 4 (7.3) | 2 (2.8) | 1 (0.8) | 2 (0.9) | 5 (1.2) | 14 (1.7) | 12 (0.8) | 12 (0.6) | <0.001 | <0.001 |
| ATC, | 0 (0) | 0 (0) | 1 (4.3) | 1 (1.8) | 3 (4.2) | 1 (0.8) | 1 (0.5) | 2 (0.5) | 1 (0.1) | 1 (0.1) | 2 (0.1) | <0.001 | <0.001 |
| Other, | 4 (17.4) | 2 (9.1) | 0 (0) | 1 (1.8) | 7 (9.9) | 4 (3.1) | 7 (3.3) | 6 (1.5) | 9 (1.1) | 7 (0.5) | 3 (0.1) | <0.001 | <0.001 |
| Unilateral | 14 (60.9) | 14 (63.6) | 13 (56.5) | 31 (56.4) | 38 (53.5) | 72 (55.4) | 122 (57.0) | 213 (52.6) | 389 (47.6) | 616 (43.6) | 991 (48.1) | 0.071 | <0.001 |
| Bilateral | 9 (39.1) | 8 (36.4) | 10 (43.5) | 24 (43.6) | 33 (46.5) | 58 (44.6) | 92 (43.0) | 192 (47.4) | 428 (52.4) | 797 (56.4) | 1069 (51.9) | ||
| Solitary | 7 (30.4) | 13 (59.1) | 11 (47.8) | 27 (49.1) | 28 (39.4) | 59 (45.4) | 105 (49.0) | 172 (42.5) | 292 (35.7) | 456 (32.3) | 749 (36.4) | <0.001 | <0.001 |
| Multiple | 16 (69.6) | 9 (40.9) | 12 (52.2) | 28 (50.9) | 43 (60.6) | 71 (54.6) | 109 (51.0) | 233 (57.5) | 525 (64.3) | 957 (67.7) | 1311 (63.6) | ||
| All cancer, | 23 | 22 | 23 | 55 | 71 | 130 | 214 | 405 | 817 | 1413 | 2060 |
ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histocytosis of the thyroid gland; PTC, papillary thyroid carcinoma.
Figure 1Trends in the diagnosis of various subtype thyroid malignancies, presented as permillage (rate per thousand) of thyroid cancer, from 1994 to 2015. ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma.
Figure 2Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (A), physical signs (B), nodule multiplicity (C), ultrasonographic sizes of nodules (D), fine-needle aspiration ratio (E) and thyroidectomy types (F) were summarised.
Clinicopathological features of PTCs from 1994 to 2015
| Period | 94–95 | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | Total | P for difference | P for trend |
| Age, year | 46.9±14.3 | 43.1±10.7 | 41.1±12.9 | 44.9±14.8 | 44.6±14.5 | 43.8±12.4 | 44.6±12.4 | 42.7±12.4 | 43.9±11.2 | 43.9±11.1 | 43.6±10.9 | 43.7±11.3 | 0.643 | |
| Male, | 5 (33.3) | 3 (17.6) | 6 (35.3) | 11 (28.2) | 18 (36) | 34 (31.8) | 60 (32.4) | 115 (30.0) | 227 (29.6) | 366 (26.6) | 616 (30.4) | 1461 (29.3) | 0.434 | 0.664 |
| Female, | 10 (66.7) | 14 (82.4)*† | 11 (64.7.0)* | 28 (71.8)* | 32 (64)*† | 73 (68.2)† | 125 (67.6)*† | 268 (70.0)*† | 541 (70.4)*† | 1010 (73.4)* | 1407 (69.6)* | 3519 (70.7) | ||
| Size‡, cm | 2.3±1.1 | 2.6±1.9 | 2.1±1.3 | 2.2±1.6 | 2.2±1.4 | 2.2±1.6 | 1.7±1.1*† | 1.5±1.0b | 1.3±0.9*† | 1.2±0.8*† | 1.2±0.9† | 1.4±1.0 | <0.001 | |
| crPTC, | 13 (86.7) | 15 (88.2) | 12 (70.6) | 32 (82.1) | 41 (82.0) | 87 (81.3) | 118 (63.8)* | 238 (62.1)† | 375 (48.8)*† | 696 (50.6)b | 1486 (73.5)* | 3113 (62.5) | <0.001 | 0.213 |
| mPTC, | 2 (13.3) | 2 (11.8) | 5 (29.4) | 7 (17.9) | 9 (18.0) | 20 (18.7) | 67 (36.2) | 145 (37.9) | 393 (51.2) | 680 (49.4) | 537 (26.5) | 1866 (37.5) | ||
| LNM, | 5 (33.3) | 5 (29.4) | 7 (41.2) | 22 (56.4) | 17 (34) | 27 (25.2) | 55 (29.7) | 96 (25.1) | 192 (25.0) | 372 (27.0) | 414 (20.5)* | 1212 (24.3) | <0.001 | <0.001 |
| No-LNM, | 10 (66.7) | 12 (70.6) | 10 (58.8) | 17 (43.6) | 33 (66) | 80 (74.8) | 130 (70.3) | 287 (74.9) | 576 (75.0) | 1004 (73.0) | 1609 (79.5) | 3768 (75.7) | ||
| Total | 15 | 17 | 17 | 39 | 50 | 107 | 185 | 383 | 768 | 1376 | 2023 | <0.001 | <0.001 |
*Percentages significantly different from the previous year.
†Percentages significantly different within the period of 08–09.
‡Mean diameter.
crPTC, clinical relevant papillary thyroid carcinoma; LN, lymph node; LNM, lymph node metastasis; mPTC, micropapillary thyroid carcinoma.
Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013
| Period | 94–95 | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | Total | P for difference | P for trend |
| crPTC, | 3 (23.1) | 5 (33.3) | 6 (50.0) | 19 (59.4) | 17 (41.5) | 24 (27.6) | 35 (29.7) | 73 (30.7) | 130 (34.7) | 243 (34.9) | 330 (22.2) | 885 (28.4) | <0.001 | <0.001 |
| mPTC, | 2 (100) | 0 (0) | 1 (20.0) | 3 (42.9) | 0 (0) | 3 (15.0) | 20 (29.9) | 23 (16.0) | 62 (15.8) | 129 (19.0) | 84 (15.6) | 327 (17.5) | 0.005 | 0.087 |
| P value | 0.032 | 0.331 | 0.252 | 0.425 | 0.017 | 0.243 | 0.978 | 0.001 | 0.000 | 0.000 | 0.001 |
crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micropapillary thyroid carcinoma.
Figure 3Determinant factors of the lymph node metastasis of papillary thyroid carcinoma (PTC) (A), micropapillary thyroid carcinoma (mPTC) (B) and clinically relevant papillary thyroid carcinoma (crPTC) (C). Logistic regression was performed to define factors associated with local lymph node metastasis (LNM).